Why Is Roivant Sciences Stock Surging Wednesday?
Roivant (ROIV) shares jump as Phase 3 CLARITY trials show brepocitinib effectively treats noninfectious uveitis & reduces steroid reliance.
Share
Why It Matters
Roivant's medicine worked well in a big human test for eye inflammation. When a medicine passes a big test, people get more hopeful about the company.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.